Prashant Nanasaheb Mohite
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prashant Nanasaheb Mohite has a total of 369 co-authors. Here are the top co-authors by number of shared publications:
Bartlomiej Zych
Royal Brompton and Harefield NHS Foundation Trust Hill End Road, Harefield, Uxbridge, London, UB9 6JH
39 shared publications- Anton Sabashnikov
Department of Cardiothoracic Surgery, University Hospital Cologne, 50937 Cologne, Germany
32 shared publications Anton Sabashnikov
Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, London, UK
31 shared publicationsAndre R. Simon
Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK
30 shared publicationsNikhil P. Patil
Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania
29 shared publicationsAndré R. Simon
Department of Cardiothoracic Transplantation and Mechanical Circulatory Support Harefield Hospital, Harefield, Uxbridge UK
28 shared publications
Latest Publications
- 3 April 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (8) , 1307-1318
The United Kingdom’s experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes
- 3 April 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (8) , 1307-1318
The United Kingdom’s experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes
- 17 November 2021
- Published by European Association of Cardiothoracic Surgery (EACTS Publishing Ltd) in Multimedia Manual of Cardio-Thoracic Surgery
- Vol. 2021
Sternal sparing bilateral symmetrical thoracotomy for implantation of left ventricular assist device
Reopening the chest in patients with left ventricular assist devices at the time of a heart transplant is challenging due to adhesions and the possibility of injury to vital structures. The sternal sparing bilateral thoracotomy approach utilized to implant a left ventricular assist device minimizes the chances of such injuries and offers a cosmetically better outcome. We demonstrate a procedure for implanting a left ventricular assist device in a 54-year-old man diagnosed with dilated cardiomyopathy who suffered rapid decompensation despite maximum medical therapy.
- 17 November 2021
- Published by European Association of Cardiothoracic Surgery (EACTS Publishing Ltd) in Multimedia Manual of Cardio-Thoracic Surgery
- Vol. 2021
Sternal sparing bilateral symmetrical thoracotomy for implantation of left ventricular assist device
Reopening the chest in patients with left ventricular assist devices at the time of a heart transplant is challenging due to adhesions and the possibility of injury to vital structures. The sternal sparing bilateral thoracotomy approach utilized to implant a left ventricular assist device minimizes the chances of such injuries and offers a cosmetically better outcome. We demonstrate a procedure for implanting a left ventricular assist device in a 54-year-old man diagnosed with dilated cardiomyopathy who suffered rapid decompensation despite maximum medical therapy.
- Open Access
- 9 June 2021
- Published by IntechOpen
Introductory Chapter: Basics of Cystic Fibrosis
Open access peer-reviewed chapter
- 9 June 2021
- Published by IntechOpen
Open AccessIntroductory Chapter: Basics of Cystic Fibrosis
Open access peer-reviewed chapter
- Open Access
- 9 June 2021
- Published by IntechOpen
Lung Transplantation in Patients with Cystic Fibrosis
Cystic fibrosis (CF) is one of the most common indications for lung transplant (LTx) and nearly one-third of the LTx worldwide are performed in people with CF (PwCF). Due to vast developments in diagnostic modalities, antibiotic therapies, and management of associated comorbidities in dedicated and experienced centres, over the past few decades, more PwCF are reaching adulthood than ever before. This has increased the burden on transplant programs particularly in a universal donor shortage scenario. To improve the donor pool a diligent and proactive donor care management, acceptance of marginal organs and utilisation of ex-vivo lung perfusion systems for organ preservation, assessment, and improvement is being advocated widely. LTx is not a readily available therapy and the average waiting time is 18 months in the UK. Therefore, it is essential that PwCF are referred for LTx assessment when their disease is stable, before respiratory deterioration leads to overall deconditioning of the patients. Once listed for LTx, it is crucial to control waiting list mortality by prioritising rapidly deteriorating patients through schemes like the lung allocation score, national urgent and super-urgent waiting lists, and institutional highlighting of deteriorating patients that do not meet other urgent criteria. LTx in PwCF is challenging due to colonisation of the respiratory tract with multi-drug resistant organisms, associated comorbidities such as diabetes, liver disease, gastro-oesophageal reflux, and distal intestinal obstruction syndrome (DIOS) and CF-specific technical difficulties (adhesions due to prior pneumothoraces or pleurodesis, or bronchial collaterals that increase surgical time). Hilar lymphadenopathy and bronchial collaterals may increase surgical time, organ ischemia time, intra and post-operative bleeding, and blood transfusions. Advances in immunosuppression, prophylactic anti-viral and anti-fungal therapies, early ambulation and rigorous physiotherapy, and meticulous postoperative follow up with spirometry, x-rays, and bronchoscopies to detect rejection at the early stage followed by its efficient treatment have helped to improve post-LTx survival in the CF patients. Constant development in the surgical field with adoption of off-pump transplantation, sternal sparing bilateral thoracotomy approach, and utilisation of mechanical circulatory assist as a bridge to transplant and as a support for primary graft failure strives for better outcomes. However, chronic lung allograft dysfunction, chronic refractory infections, malignancies, and CF associated comorbidities remain major determinants of post-LTx long term survival. Despite this, CF patients are often good candidates for re-do LTx with improving survival outcomes. In this chapter, we are compiling the different aspects of LTx in PwCF emphasising the advances in bridge to transplantation, the surgical approach, management of primary graft failure, and immunosuppression as well as complications post-transplant.
- 9 June 2021
- Published by IntechOpen
Open AccessLung Transplantation in Patients with Cystic Fibrosis
Cystic fibrosis (CF) is one of the most common indications for lung transplant (LTx) and nearly one-third of the LTx worldwide are performed in people with CF (PwCF). Due to vast developments in diagnostic modalities, antibiotic therapies, and management of associated comorbidities in dedicated and experienced centres, over the past few decades, more PwCF are reaching adulthood than ever before. This has increased the burden on transplant programs particularly in a universal donor shortage scenario. To improve the donor pool a diligent and proactive donor care management, acceptance of marginal organs and utilisation of ex-vivo lung perfusion systems for organ preservation, assessment, and improvement is being advocated widely. LTx is not a readily available therapy and the average waiting time is 18 months in the UK. Therefore, it is essential that PwCF are referred for LTx assessment when their disease is stable, before respiratory deterioration leads to overall deconditioning of the patients. Once listed for LTx, it is crucial to control waiting list mortality by prioritising rapidly deteriorating patients through schemes like the lung allocation score, national urgent and super-urgent waiting lists, and institutional highlighting of deteriorating patients that do not meet other urgent criteria. LTx in PwCF is challenging due to colonisation of the respiratory tract with multi-drug resistant organisms, associated comorbidities such as diabetes, liver disease, gastro-oesophageal reflux, and distal intestinal obstruction syndrome (DIOS) and CF-specific technical difficulties (adhesions due to prior pneumothoraces or pleurodesis, or bronchial collaterals that increase surgical time). Hilar lymphadenopathy and bronchial collaterals may increase surgical time, organ ischemia time, intra and post-operative bleeding, and blood transfusions. Advances in immunosuppression, prophylactic anti-viral and anti-fungal therapies, early ambulation and rigorous physiotherapy, and meticulous postoperative follow up with spirometry, x-rays, and bronchoscopies to detect rejection at the early stage followed by its efficient treatment have helped to improve post-LTx survival in the CF patients. Constant development in the surgical field with adoption of off-pump transplantation, sternal sparing bilateral thoracotomy approach, and utilisation of mechanical circulatory assist as a bridge to transplant and as a support for primary graft failure strives for better outcomes. However, chronic lung allograft dysfunction, chronic refractory infections, malignancies, and CF associated comorbidities remain major determinants of post-LTx long term survival. Despite this, CF patients are often good candidates for re-do LTx with improving survival outcomes. In this chapter, we are compiling the different aspects of LTx in PwCF emphasising the advances in bridge to transplantation, the surgical approach, management of primary graft failure, and immunosuppression as well as complications post-transplant.
- 27 April 2021
- Published by European Association of Cardiothoracic Surgery (EACTS Publishing Ltd) in Multimedia Manual of Cardio-Thoracic Surgery
- Vol. 2021
Ex vivo lung perfusion made easy
Ex vivo lung perfusion is an indispensable tool in the armamentarium of any lung transplant center. It helps to increase an already shrinking donor pool by offering a chance to assess suboptimal donor lungs in a systematic manner and improve them by treating them with low-molecular-weight perfusate. We offer a stepwise guide to carry out ex vivo lung perfusion on the donor lungs and criteria to accept them for transplants.
- 27 April 2021
- Published by European Association of Cardiothoracic Surgery (EACTS Publishing Ltd) in Multimedia Manual of Cardio-Thoracic Surgery
- Vol. 2021
Ex vivo lung perfusion made easy
Ex vivo lung perfusion is an indispensable tool in the armamentarium of any lung transplant center. It helps to increase an already shrinking donor pool by offering a chance to assess suboptimal donor lungs in a systematic manner and improve them by treating them with low-molecular-weight perfusate. We offer a stepwise guide to carry out ex vivo lung perfusion on the donor lungs and criteria to accept them for transplants.
- 29 September 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (12) , 1788-1798
Utilization of extracorporeal membrane oxygenation in DCD and DBD lung transplants: a 2‐year single‐center experience
Donation after circulatory death (DCD) has the potential to expand the lung donor pool. We aimed to assess whether DCD affected the need for perioperative extracorporeal membrane oxygenation (ECMO) and perioperative outcomes in lung transplantation (LTx) as compared to donation after brain death (DBD). All consecutive LTx performed between April 2017 and March 2019 at our tertiary centre were analysed. Donor and recipient preoperative characteristics, utilization of ECMO and perioperative clinical outcomes were compared between DCD and DBD LTx. Multivariate models (frequentist and Bayes) were fitted to evaluate an independent effect of DCD on the intra‐ and postoperative need for ECMO. Out of 105 enrolled patients, 25 (23.8%) were DCD LTx. Donors’ and preoperative recipients’ characteristics were comparable between the groups. Intraoperatively, mechanical circulatory support (MCS) was more common in DCD LTx (56.0% vs. 36.2%), but the adjusted difference was minor (RR=1.16, 95%CI 0.64‐2.12; p=0.613). MCS duration, first and second lung ischemia time were longer in the DCD group. Postoperatively, DCD recipients more commonly required ECMO (32.0% vs. 7.5%) and the difference remained considerable after adjustment for the pre‐ and intraoperative covariates: RR=4.11 (95%CI 0.95‐17.7), p=0.058, Bayes RR=4.15 (95%CrI 1.28‐13.0). Sensitivity analyses (two DCD‐DBD matching procedures) supported a higher risk of postoperative ECMO need in DCD patients. Incidence of delayed chest closure, postoperative chest drainage, and renal replacement therapy was higher in the DCD group. Early postoperative outcomes after DCD LTx appeared generally comparable to those after DBD LTx. DCD was associated with a higher need for postoperative ECMO which could influence clinical outcomes. However, as the DCD group had a significantly higher use of EVLP with more common ECMO preoperatively, this might have contributed to worse outcomes in the DCD group.
- 29 September 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (12) , 1788-1798
Utilization of extracorporeal membrane oxygenation in DCD and DBD lung transplants: a 2‐year single‐center experience
Donation after circulatory death (DCD) has the potential to expand the lung donor pool. We aimed to assess whether DCD affected the need for perioperative extracorporeal membrane oxygenation (ECMO) and perioperative outcomes in lung transplantation (LTx) as compared to donation after brain death (DBD). All consecutive LTx performed between April 2017 and March 2019 at our tertiary centre were analysed. Donor and recipient preoperative characteristics, utilization of ECMO and perioperative clinical outcomes were compared between DCD and DBD LTx. Multivariate models (frequentist and Bayes) were fitted to evaluate an independent effect of DCD on the intra‐ and postoperative need for ECMO. Out of 105 enrolled patients, 25 (23.8%) were DCD LTx. Donors’ and preoperative recipients’ characteristics were comparable between the groups. Intraoperatively, mechanical circulatory support (MCS) was more common in DCD LTx (56.0% vs. 36.2%), but the adjusted difference was minor (RR=1.16, 95%CI 0.64‐2.12; p=0.613). MCS duration, first and second lung ischemia time were longer in the DCD group. Postoperatively, DCD recipients more commonly required ECMO (32.0% vs. 7.5%) and the difference remained considerable after adjustment for the pre‐ and intraoperative covariates: RR=4.11 (95%CI 0.95‐17.7), p=0.058, Bayes RR=4.15 (95%CrI 1.28‐13.0). Sensitivity analyses (two DCD‐DBD matching procedures) supported a higher risk of postoperative ECMO need in DCD patients. Incidence of delayed chest closure, postoperative chest drainage, and renal replacement therapy was higher in the DCD group. Early postoperative outcomes after DCD LTx appeared generally comparable to those after DBD LTx. DCD was associated with a higher need for postoperative ECMO which could influence clinical outcomes. However, as the DCD group had a significantly higher use of EVLP with more common ECMO preoperatively, this might have contributed to worse outcomes in the DCD group.
- 3 September 2020
- Published by Wiley in Artificial Organs
- Vol. 45 (3) , 271-277
Use of oxygenator with short‐term ventricular assist devices
Venoarterial extracorporeal membrane oxygenation (VA‐ECMO) serves as a conventional short‐term mechanical circulatory assist to support heart and lung functions. The short‐term ventricular assist devices (ST‐VAD) can, on the contrary, offer only circulatory support. A combination of VAD and oxygenator (Oxy‐VAD) could help overcome this potential disadvantage. This is a retrospective case note study of patients supported on ST‐VAD which required adding an oxygenator for extra respiratory support. The oxygenator was introduced in the ST‐VAD circuit, either on the left or the right side. Twenty‐two patients with the etiology of refractory cardiogenic shock in decompensation were supported on Oxy‐VAD between years 2009 and 2019 at tertiary care . All patients were classified into class‐I INTERMACS with a mean SOFA Score of 14 ± 2.58. 86.4% of patients were already on mechanical support pre‐ST‐VAD implant, 80% on VA‐ECMO. The BiVAD implant accounted for 63.6%, followed by LVAD and RVAD with 27.3% and 9.1%. Mean duration of the ST‐VAD was 8.5 days. The oxygenator was introduced in 14 RVAD and 8 LVAD circuits. The oxygenator was successfully weaned in 54.5% while ST‐VAD was explanted in 31.8%. Discharge to home survival was 22.7%. Oxy‐VAD proves a viable, and probably, a better option to VA‐ECMO in acute cardiorespiratory decompensation. It offers organ‐specific tailor‐made support to the right and/or left heart and/or lungs. While on Oxy‐VAD support, each organ performance can be assessed independently, and the assistance of the specifically improved organ can be weaned off without discontinuing the support for the rest.
- 3 September 2020
- Published by Wiley in Artificial Organs
- Vol. 45 (3) , 271-277
Use of oxygenator with short‐term ventricular assist devices
Venoarterial extracorporeal membrane oxygenation (VA‐ECMO) serves as a conventional short‐term mechanical circulatory assist to support heart and lung functions. The short‐term ventricular assist devices (ST‐VAD) can, on the contrary, offer only circulatory support. A combination of VAD and oxygenator (Oxy‐VAD) could help overcome this potential disadvantage. This is a retrospective case note study of patients supported on ST‐VAD which required adding an oxygenator for extra respiratory support. The oxygenator was introduced in the ST‐VAD circuit, either on the left or the right side. Twenty‐two patients with the etiology of refractory cardiogenic shock in decompensation were supported on Oxy‐VAD between years 2009 and 2019 at tertiary care . All patients were classified into class‐I INTERMACS with a mean SOFA Score of 14 ± 2.58. 86.4% of patients were already on mechanical support pre‐ST‐VAD implant, 80% on VA‐ECMO. The BiVAD implant accounted for 63.6%, followed by LVAD and RVAD with 27.3% and 9.1%. Mean duration of the ST‐VAD was 8.5 days. The oxygenator was introduced in 14 RVAD and 8 LVAD circuits. The oxygenator was successfully weaned in 54.5% while ST‐VAD was explanted in 31.8%. Discharge to home survival was 22.7%. Oxy‐VAD proves a viable, and probably, a better option to VA‐ECMO in acute cardiorespiratory decompensation. It offers organ‐specific tailor‐made support to the right and/or left heart and/or lungs. While on Oxy‐VAD support, each organ performance can be assessed independently, and the assistance of the specifically improved organ can be weaned off without discontinuing the support for the rest.
- 5 May 2020
- Published by Wiley in Artificial Organs
- Vol. 44 (9) , 1006-1008
Bridge to heart transplantation using the Levitronix CentriMag short‐term ventricular assist device
- 5 May 2020
- Published by Wiley in Artificial Organs
- Vol. 44 (9) , 1006-1008
Bridge to heart transplantation using the Levitronix CentriMag short‐term ventricular assist device
- Open Access
- 4 December 2019
- Published by IntechOpen
Isn’t Limb as Precious as Life?
As utilisation of peripheral extra-corporeal life support (ECLS) is becoming clinical routine, its associated complications become more frequent. Distal limb perfusion in femoral cannulation remains one of the Achille’s heels in patients with peripheral ECLS. Unless detected early, limb ischemia may result in loss of limb and sometimes life. A protocol-based approach, precautions during ECLS implantation and explantation procedures and continuous monitoring of the limb during ECLS support are key elements in preventing this complication. Utilisation of a distal limb perfusion cannula helps in prevention as well as management of limb ischemia; however, it may sometimes cause more damage than help. Management and consequence of limb ischemia essentially depends on its severity at the time of detection as well as time of intervention. This chapter offers a brief review of the burden of limb ischemia, means to prevent and approaches to manage it.
- 4 December 2019
- Published by IntechOpen
Open AccessIsn’t Limb as Precious as Life?
As utilisation of peripheral extra-corporeal life support (ECLS) is becoming clinical routine, its associated complications become more frequent. Distal limb perfusion in femoral cannulation remains one of the Achille’s heels in patients with peripheral ECLS. Unless detected early, limb ischemia may result in loss of limb and sometimes life. A protocol-based approach, precautions during ECLS implantation and explantation procedures and continuous monitoring of the limb during ECLS support are key elements in preventing this complication. Utilisation of a distal limb perfusion cannula helps in prevention as well as management of limb ischemia; however, it may sometimes cause more damage than help. Management and consequence of limb ischemia essentially depends on its severity at the time of detection as well as time of intervention. This chapter offers a brief review of the burden of limb ischemia, means to prevent and approaches to manage it.